Cellectis (CLLS) Reports Q3 Loss of $0.36/Share
Tweet
Share
E-mailGet Alerts CLLS Hot Sheet
Join SI Premium – FREE
Cellectis (NASDAQ: CLLS) reported Q3 EPS of ($0.36), versus ($0.36) reported last year. Revenue for the quarter came in at $9.98 million, versus $11.31 million reported last year.
For earnings history and earnings-related data on Cellectis (CLLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
- Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c
- Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
